Dublin, March 21, 2019 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market by Product, Procedures, Cancer - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The global interventional oncology market is projected to reach USD 2,948.9 million by 2024 from USD 2,097.0 million in 2019, at a CAGR of 6.8% from 2018 to 2024.

The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and the increasing government investments and funding for interventional oncology and related cancer research.

On the basis of region, the interventional oncology market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the largest share of 43.7% of the interventional oncology market in 2018. The large share of this segment can be attributed to the rising patient preference for minimally invasive procedures, expansion of the target patient population, technological advancements, increasing number of government initiatives to support interventional oncology procedures, and the growing availability of novel immunotherapy agents.

Asia Pacific accounted for a share of 18.7% of the global interventional oncology market in 2018 and is expected to grow at the highest CAGR of 9.6% during the forecast period. Emerging economies in the region such as India, China, and South Korea along with developed markets such as Japan and Australia are offering high-growth opportunities for market players in the field of interventional oncology. This can be attributed to factors such as the increasing adoption of interventional oncology procedures, growing incidence of cancer, and the growing geriatric population.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Interventional Oncology: Market Overview
4.2 Geographic Analysis: Interventional Oncology Market, By Product
4.3 Asia Pacific: Ablation Devices Market, By Type (2018)
4.4 Europe: Interventional Oncology Market, By Cancer Type (2018)
4.5 Interventional Oncology Market, By Procedure, 2019 vs 2024 (USD Million)
4.6 Geographical Snapshot of the Interventional Oncology Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Patient Preference for Minimally Invasive Procedures
5.2.1.2 Expansion of the Target Patient Population
5.2.1.3 Increasing Public-Private Funding and Government Support for Interventional Oncology
5.2.1.4 Technological Advancements in Interventional Oncology
5.2.2 Restraints
5.2.2.1 Dearth of Well-Trained and Skilled Radiologists and Oncologists
5.2.2.2 Unfavorable Regulations
5.2.3 Opportunities
5.2.3.1 Emerging Economies Offer High Growth Potential
5.2.3.2 Rising Awareness About the Benefits of Interventional Oncology
5.2.4 Challenges
5.2.4.1 Limited Clinical Data to Support Therapeutic Efficacy
5.2.4.2 Strong Market Positioning of Alternative Therapies
5.3 Market Trends
5.3.1 Personalized Or Precision Interventional Oncology

6 Interventional Oncology Market, By Product
6.1 Introduction
6.2 Embolization Devices
6.2.1 Interventional Oncology Embolization Devices Market Split, By Procedure
6.2.2 Interventional Oncology Embolization Devices Market Split, By Cancer Type
6.2.3 Radioembolic Agents
6.2.4 Non-Radioactive Embolic Agents
6.3 Ablation Devices
6.3.1 Technological Advancements in Ablation Devices - A Key Driver for Market Growth
6.3.2 Radiofrequency (RF) Ablation Devices
6.3.3 Microwave Ablation Devices
6.3.4 Cryoablation Devices
6.3.5 Other Ablation Devices
6.4 Support Devices
6.4.1 Interventional Oncology Support Devices Market Split, By Procedure
6.4.2 Interventional Oncology Support Devices Market Split, By Cancer Type
6.4.3 Microcatheters
6.4.4 Guidewires
6.4.4.1.1 Guidewires Market Split, By Procedure
6.4.4.1.2 Guidewires Market Split, By Cancer Type

7 Interventional Oncology Market, By Procedure
7.1 Introduction
7.2 Thermal Tumor Ablation
7.2.1 Increasing Clinical Evidence is A Major Factor Driving Market Growth
7.3 Non-Thermal Tumor Ablation
7.3.1 Nanoknife has Emerged as A Potential Alternative to Thermal Tumor Ablation Techniques
7.4 Transcatheter Arterial Chemoembolization
7.4.1 Ability to Treat Small and Large-Sized Tumors - A Major Factor Driving the Demand for Tace Procedures
7.5 Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
7.5.1 Tare Shows Greater Clinical Efficacy as Compared to Tace
7.6 Transcatheter Arterial Embolization/Bland Embolization
7.6.1 Increasing Clinical Evidence for Tare and Tace to Restrain Growth of This Market

8 Interventional Oncology Market, By Cancer Type
8.1 Introduction
8.1.1 Liver Cancer
8.1.1.1 Increasing Disease Prevalence and Rising Research Activity are Driving Market Growth
8.1.2 Lung Cancer
8.1.2.1 Increasing Number of Cancer Cases Will Drive the Demand for Interventional Oncology Procedures
8.1.3 Bone Cancer
8.1.3.1 Interventional Oncology Procedures Can Eliminate Tumors Directly and Relieve Pain
8.1.4 Kidney Cancer
8.1.4.1 Interventional Oncology Procedures are Appropriate for Patients With A Genetic Disposition for Multiple Tumors
8.1.5 Other Cancers

9 Interventional Oncology Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 US to Dominate the North American Interventional Oncology Market
9.2.2 Canada
9.2.2.1 Public-Private Initiatives to Support the Adoption of Interventional Oncology Procedures in Canada
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany is the Fastest-Growing Market in Europe
9.3.2 UK
9.3.2.1 Increasing Awareness and Support for Cancer-Related Activities to Drive Market Growth in the UK
9.3.3 France
9.3.3.1 Radiofrequency Ablation Dominated the Ablation Devices Market in France
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Rising Geriatric Population and Universal Healthcare Reimbursement are the Major Driving Factors
9.4.2 China
9.4.2.1 Increasing Cancer Incidence and Growing Patient Population to Drive Market Growth in China
9.4.3 India
9.4.3.1 Improving Research Capabilities Coupled With the Expansion of Key Players to Drive Market Growth in India
9.4.4 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.1.1 Brazil to Account for the Largest Share of the Latin American Interventional Oncology Market
9.5.2 Mexico
9.5.2.1 Growing Awareness Campaigns and Rising Incidence of Cancer to Drive Market Growth in Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Improving Healthcare Infrastructure and Rising Incidence of Cancer are Driving Growth in the Middle East and Africa

10 Competitive Landscape
10.1 Overview
10.2 Global Market Share Analysis, 2017
10.3 Competitive Scenario (2015 - 2019)
10.4 Vendor Dive Overview
10.5 Vendor Inclusion Criteria
10.6 Vendor Dive

11 Company Profiles
11.1 Healthtronics, Inc.
11.2 Trod Medical
11.3 Sanarus Technologies, Inc.
11.4 Teleflex, Inc.
11.5 Imbiotechnologies Ltd.
11.6 Medwaves, Inc.
11.7 Icecure Medical
11.8 Terumo Corporation
11.9 Medtronic PLC
11.10 BTG PLC
11.11 Johnson & Johnson
11.12 Merit Medical Systems, Inc.
11.13 Boston Scientific Corporation
11.14 Angiodynamics, Inc.
11.15 Cook Medical

For more information about this report visit https://www.researchandmarkets.com/research/vmkgsm/interventional?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology